A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 29.4B | 29.4B | 28.8B | 27.1B | 27.3B | 27.3B |
| Net Income | 8.5B | 8.5B | 480M | 5.7B | 4.6B | 6.2B |
| EPS | $6.78 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
| Free Cash Flow | 9.5B | 9.5B | 10.3B | 7.4B | 8.3B | 10.8B |
| ROIC | 20.3% | 21.6% | 3.0% | 14.7% | 13.6% | 17.4% |
| Gross Margin | 78.8% | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% |
| Debt/Equity | 1.22 | 1.22 | 1.48 | 1.17 | 1.29 | 1.34 |
| Dividends/Share | $3.19 | $3.16 | $3.08 | $3.00 | $2.92 | $2.84 |
| Operating Income | 10.0B | 10.0B | 1.7B | 7.6B | 7.3B | 9.9B |
| Operating Margin | 34.0% | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% |
| ROE | 37.5% | 40.5% | 2.5% | 24.8% | 21.6% | 29.5% |
| Shares Outstanding | 1,255M | 1,255M | 1,263M | 1,259M | 1,262M | 1,263M |
GILEAD SCIENCES, INC. passes 6 of 9 quality checks, suggesting mixed fundamentals.
GILEAD SCIENCES, INC. trades at 20.5x trailing earnings, compared to its 15-year median P/E of 14.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 18.3x vs a median of 8.1x. The company's 5-year average ROIC is 14.1% with a gross margin of 77.6%. Total shareholder yield (dividends + buybacks) is 3.4%. At current prices, the estimated annualized return to fair value is +2.1%.
GILEAD SCIENCES, INC. (GILD) has a current P/E ratio of 20.5, compared to its historical median P/E of 14.0. The stock is currently considered Expensive based on its historical valuation range.
GILEAD SCIENCES, INC. (GILD) has a 5-year average return on invested capital (ROIC) of 14.1%. This indicates solid capital allocation.
GILEAD SCIENCES, INC. (GILD) has a market capitalization of $174.5B. It is classified as a large-cap stock.
Yes, GILEAD SCIENCES, INC. (GILD) pays a dividend with a trailing twelve-month yield of 2.29%. The company also returns capital through share buybacks, with a buyback yield of 1.10%.
Based on historical P/E analysis, GILEAD SCIENCES, INC. (GILD) appears expensive. The current P/E of 20.5 is 46% above its historical median of 14.0. The estimated fair value CAGR (P/E method) is -1.8%.
GILEAD SCIENCES, INC. (GILD) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
GILEAD SCIENCES, INC. (GILD) reported annual revenue of $29.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
GILEAD SCIENCES, INC. (GILD) has a net profit margin of 28.9%. This is a strong margin indicating high profitability.
GILEAD SCIENCES, INC. (GILD) generated $9.5 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GILEAD SCIENCES, INC. (GILD) has a debt-to-equity ratio of 1.22. This indicates moderate leverage.
GILEAD SCIENCES, INC. (GILD) reported earnings per share (EPS) of $6.78 in its most recent fiscal year.
GILEAD SCIENCES, INC. (GILD) has a return on equity (ROE) of 40.5%. This indicates the company generates strong returns for shareholders.
GILEAD SCIENCES, INC. (GILD) has a 5-year average gross margin of 77.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for GILEAD SCIENCES, INC. (GILD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GILEAD SCIENCES, INC. (GILD) has a book value per share of $18.09, based on its most recent annual SEC filing.